BIOTRICITY INC. SEC 10-Q Report

Biotricity Inc., a leading provider of remote monitoring solutions for preventative care, has released its latest Form 10-Q report, showcasing notable improvements in both financial performance and business operations. The report highlights the company's strides in revenue growth, cost management, and product commercialization efforts, despite ongoing challenges related to working capital and accumulated deficits. Financial Highlights Revenue: $7.76 million, reflecting an increase from $6.47 million in the prior year period, driven by higher technology fees and device sales.Gross Profit: $6.30 million, up from $4.82 million, indicating improved cost management and increased sales volume.Profit (Loss) from Operations: $0.56 million, compared to a loss of $1.42 million in the previous year, highlighting a significant turnaround in operational efficiency.Net Loss Before Income Taxes: $(1.36) million, an improvement from a loss of $(5.26) million, due to better cost control and increased revenue.Net Loss Attributable to Common Stockholders: $(1.53) million, compared to $(8.60) million, showing a substantial reduction in losses.Loss Per Share, Basic and Diluted: $(0.057), improved from $(0.469), reflecting the company's efforts in reducing losses per share. Business Highlights Revenue Segments: The company reported revenue from two main segments: technology fees and device sales. Technology fees accounted for a significant portion of the revenue, with $6,882,846 for the six months ended September 30, 2025, compared to $6,081,064 for the same period in 2024. Device sales also increased, reaching $876,942 for the six months ended September 30, 2025, up from $387,525 in the prior year.Geographical Performance: The company operates primarily in the United States, with its property and equipment and operating right of use lease assets located there. The Canadian-based subsidiary's functional currency is the Canadian dollar, indicating some level of international operations.New Product Launches: The company is focused on the commercialization of its Bioflux, Biocore, and Biocare product lines, indicating ongoing efforts to expand its product offerings in the remote monitoring segment of preventative care.Future Outlook: Management anticipates continued revenue growth and improved liquidity through business development and additional equity and debt capitalization. The company plans to devote significant resources to capital expenditures, research and development, and marketing and sales as it proceeds with the commercialization of its product lines.Operational Challenges: The company faces challenges related to its working capital deficiency and accumulated deficit, which raise substantial doubt about its ability to continue as a going concern. Management is focused on addressing these challenges through revenue growth and financing activities.SEC Filing: BIOTRICITY INC. [ BTCY ] - 10-Q - Nov. 14, 2025